It is also known that certain antineoplastic drugs can mimic uveitis, such as vemurafenib (anti-BRAF), dabrafenib (anti-BRAF), nivolumab (anti-PD-1), ipilimumab (anti-CTLA-4), osimertinib (anti-EGFR), trametinib (anti-MEK), and rituximab (anti-CD20) [20,21]. This evidence concerns the gene BRAF and uveitis.